Acute GvHD occurs in 450% of patients 1 and mainly affects the skin, gastrointestinal (GI) tract and liver. If skin is the predominant or the only organ involved, skin-directed therapy such as phototherapy is an option. Phototherapy has been used mainly as an adjuvant treatment in steroid-refractory or steroiddependent GvHD, with responses varying from 50 to 100%. 2, 3 Psoralen with UVA (PUVA) has been shown to be efficacious in both acute and chronic GvHD; 4-6 however, the theoretical risk of skin cancer and potential hepatic toxicity has prompted the use of narrow band UVB (NBUVB) in cutaneous GvHD with proven efficacy in a few series of acute GvHD and overlap syndromes recently in adults and children. 7, 8 In this retrospective study, we analyzed the efficacy of NBUVB as a treatment option in acute cutaneous GVHD.
Psoralen with UVA (PUVA) has been shown to be efficacious in both acute and chronic GvHD; [4] [5] [6] however, the theoretical risk of skin cancer and potential hepatic toxicity has prompted the use of narrow band UVB (NBUVB) in cutaneous GvHD with proven efficacy in a few series of acute GvHD and overlap syndromes recently in adults and children. 7, 8 In this retrospective study, we analyzed the efficacy of NBUVB as a treatment option in acute cutaneous GVHD.
Twenty patients who received NBUVB phototherapy for the treatment of acute GvHD following stem cell transplantation (SCT) with predominant skin manifestations between May 2010 and June 2013 were studied after approval by the institutional review board. During this period, 420 patients underwent SCT of which 153 (36.4%) developed acute GvHD and 120 (28.5%) had skin GvHD. The diagnosis of acute GvHD was based on clinical criteria supported by biopsy (n = 18) and on clinical criteria alone (n = 2) after excluding other etiologies such as viral exanthems and drug rashes. Transient rashes lasting o 72 h were excluded. Clinical staging was done according to the Glucksberg criteria. 9 Patients received phototherapy as primary treatment along with topical steroids or topical tacrolimus when GvHD involved the skin predominantly (stage 2-3) and extracutaneous manifestations were relatively stable. It was given with oral steroids in the presence of stage 2-3 skin GvHD and significant GI or liver GvHD. It was also given for the appearance of skin GvHD following tapering of systemic steroids or other immunosuppressants (Table 1) . Patients with stage 4 skin GvHD or who were unwell were not considered for treatment with NBUVB. NBUVB was administered in a full body upright UV therapy cabinet (Daavlin 3 series 311/350, Bryan, OH, USA) fitted with 24 flourescent bulbs emitting light with a 311-nm wavelength. All patients being of skin type IV or V, NBUVB was set at the lowest dose initially, the initial dose being 60 mJ/cm 2 and then gradually increased by 20-30 mJ/cm 2 , and was given on alternate days either twice or thrice weekly. It was discontinued if the patient was clinically clear of rash or developed significant GvHD in other organ systems or if patient was unable to come for the phototherapy sessions. A complete remission (CR) was defined as complete clearance of lesions with no evidence of cutaneous GvHD at the end of the treatment. Partial remission was defined as reduction of lesions, either a reduction in the erythema or in duration of lesions, or in percentage of body surface area involved by the end of treatment, and no response when there was no reduction with phototherapy or there was worsening of skin lesions after discontinuation of phototherapy. Regular follow-up of these patients was done to look for recurrence of acute GvHD, development of chronic GvHD and any untoward effects on the skin. Demographic data and response to phototherapy were recorded.
Twenty patients including 13 males and 7 females with a median age of 18.5 years (range 5-49) were included. Baseline characteristics are given in Table 1 . The median time to onset of cutaneous GvHD was 40 days (range 9-114). One patient had hyperacute GvHD following second transplant. Fourteen patients had isolated skin GvHD at the onset of phototherapy, whereas six showed features of visceral involvement (liver and GI). Eleven patients received NBUVB alone as primary therapy for acute GvHD, which included seven patients with isolated skin GvHD and four with flare-up of skin GvHD during calcineurin taper. In nine patients, phototherapy was combined with steroids (Table 1) ; six had evidence of visceral involvement (liver and GI) and one had steroid-refractory GvHD.
NBUVB was administered at a median of 30 days post SCT (range: 15-117). The median number of treatment sessions were 5 (range: 5-15) and median duration of treatment was 20 days (range: 8-60). All patients tolerated the NBUVB well and none discontinued phototherapy due to side effects. Response was seen in all patients (100%) with 17 (85%) showing complete remission, whereas 3 (15%) achieved partial remission. The median time to response was 16 days (range: 6-30). The partial responders discontinued phototherapy after 5, 5 and 7 sessions, respectively, and were initiated on oral steroids in the first two and topical steroids in the latter. There was significant relief of pruritus in all five patients who presented with severe itching. In 11 patients (5 with stage 2 and 6 with stage 3 skin GvHD) who received phototherapy as primary treatment, systemic steroids could be avoided as GvHD was well controlled with NBUVB and topical medications. All these patients were simultaneously treated with topical steroids and phototherapy. In six patients with stage 3 skin GvHD, phototherapy was given instead of systemic steroids in view of high-risk disease (n = 2), flare-up of skin lesions during tapering of immunosuppression (n = 2), second bone marrow transplantation (n = 1) and at the transplant physician's decision (n = 1). Nine patients received systemic corticosteroids along with NBUVB, and in 7 (77.7%) the doses of corticosteroids could be reduced substantially by the end of phototherapy.
At a median follow-up of 31 months (range: 10-50), 14 patients (70%) remain in complete remission with regard to skin GvHD, whereas 3 patients developed features of limited chronic cutaneous GvHD (all sclerotic). Two patients died due to relapse of disease, whereas one patient died due to renal failure. Nine patients have oral chronic GvHD, whereas two patients have lung GvHD at last follow-up. There was no incidence of skin cancer after NBUVB therapy during the period of follow-up.
Phototherapy is a viable option for steroid-refractory and steroid-dependent GvHD; [2] [3] [4] [5] [6] however, there are limited data on its use as primary therapy for acute cutaneous GvHD and for prophylaxis of GvHD. This study supports the view that NBUVB can be an attractive treatment option for acute GvHD limited to the skin. As corticosteroids are associated with considerable toxicity and infectious complications, skin-directed therapies such as topical agents or UV light may be useful as first-line treatment for acute GvHD while patients are on systemic immunosuppression. In 11 of our patients, we were able to avoid the use of systemic corticosteroids in mild-moderate GvHD similar to the study by Schlaak et al., in which systemic steroids could be avoided in 67% of patients with the use of UVA1 as primary therapy. 10 We also found that in patients with severe skin GvHD, use of phototherapy may help in rapid tapering of systemic steroids similar to Feldstein et al. study. 7 We cannot distinguish the effects of steroids and phototherapy when they are given together. In patients with late-onset acute skin GvHD without involvement of other organs, phototherapy can be used instead of increasing the immunosuppression further as seen in three of our patients. NBUVB was found useful in the treatment of skin GvHD in several case series although randomized controlled trials are lacking (Table 2) . Recent studies have shown 90% CR in steroid-refractory acute GvHD (11), which is similar to our data.
The efficacy of NBUVB in treating inflammatory disorders of the skin is believed to be due to its antiproliferative and immunomodulatory effects. It suppresses interleukin [IL-8 and IL-12] and interferon-gamma, leading to apoptosis of skin homing lymphocytes, reducing the number of Langerhans cells in the epidermis and dermis. A very recent prospective controlled study 12 showed that broadband UVB irradiation during allogeneic SCT could improve acute (cutaneous) GvHD outcomes by depletion of epidermal dendritic cells (Langerhans cells). They also proposed that the positive effect of UVB could be due to the induction of T-regulatory cells as detected by flow cytometry, in addition to the effect on Langerhans cells. 12 The advantage of NBUVB is that it doesn't require prior sensitization with a drug. The immunomodulatory effects of UV radiation may also permit the reduction or replacement of standard systemic Abbreviations: BBUVB = broadband UVB; BSA = body surface area; LC = Langerhans cells; NBUVB = narrow band UVB; OR = overall response, pt = patient, PUVA-Psoralen+UVA; Rx = prescription; SD = steroid dependent; SR = steroid refractory. Abbreviations: AA = aplastic anemia; APML = acute promyelocytic leukemia; BM = bone marrow; BMT2 = bone marrow transplantation2; Bu = busulfan; Cond. = condition; CsA = cyclosporine; Cy = cyclophosphamide; Diag. = diagnosis; F = female; FA = fanconi anemia; Flu = fludarabine; GI = gastrointestinal GvHD; Haplo = haploidentical transplant; JMML = juvenile myelomonocytic leukemia; M = male; Mel = melphalan; MRD = matched related transplant; MTX = methotrexate; MUD = matched unrelated transplant; PNH = paroxysmal nocturnal hemoglobinuria; PTCy = post-transplant cyclophosphamide; Pt. no. = patient number; proph. = prophylaxis; Tac = tacrolimus; Thal major = thalassemia major; Tre = treosulphan; TT = thiotepa; UDL = undifferentiated leukemia.
immunosuppressive therapy. This is particularly advantageous when patients develop CMV viremia. In these patients, steroid doses could be rapidly tapered after starting phototherapy.
In conclusion, our results suggest that NBUVB is feasible and well tolerated, and could be an effective treatment option for acute GvHD limited to skin in stage 2 and in selected patients with stage 3 and could be used as first-line treatment, when there is no systemic involvement. This study is limited largely by its retrospective nature and hence a selection bias of patients could not be avoided. We have recently initiated a prospective trial (CTRI no.2015/02/008485),which attempts to study the utility of NBUVB in acute and chronic GvHD. Large studies are needed to understand better the impact of NBUVB in acute cutaneous GvHD.
